Iron bioavailability from an instant milk beverage containing FERRI PRO Trademark

Not Applicable

Completed

• Conditions: Iron deficiency; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12615000690550
• Lead Sponsor: Massey University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-07-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

Healthy, non-anaemic, non-iron deficient (serum ferritin concentrations are > 12 ug/L and < 150 ug/L; haemoglobin > 120 g/L.
Stable body weight and normal body mass index (18.5-25 kg/m2).
Caucasian/European descent.
C-reactive protein concentrations < 5 mg/L.

Exclusion Criteria

History of gastrointestinal disorders including ulcers or gastrointestinal surgery.
Established health problems likely to influence iron status such as inflammatory bowel disease, endocrine disorders, diabetes, celiac disease, red blood cell disorders, menorrhagia, haemorrhoids, haematuria or have had malaria.
Donated blood or had significant blood loss during the 6 months prior to the study.
Participated in a study involving administration of stable isotopes.
Participated in another clinical trial during the three months leading up to the start of the study.
Consumed antibiotics one month before the study and/or during the study.
Be anaemic
Be pregnant or have been pregnant in the 12 months prior to the study.
Be breastfeeding.
Regular consumers of iron supplements (define as >20 mg elemental iron at least 3-4 times per week for one month prior to the trial.
Smoke cigarettes.
Consume more than two units of alcohol per day.
Vegetarian or vegan.
Allergies to dairy products.
On a controlled diet or dietary weight loss regimen within 4 weeks before and/or during the study.
Experienced significant weight loss during the 6 months prior to the study.
Taking any medications regularly, including antacids, except oral contraceptives.
Have an aversion to blood sample collection.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
% iron absorption determined via erythrocyte incorporation of isotopic labels (57Fe and 58Fe).[14 days after the intake of the last test meal.]

Secondary Outcome Measures

Name	Time	Method
il[Nil]